Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.
!!!All Science Journal Classification (ASJC) codes